That BLA little Ampio promised? That’s not going anywhere as FDA slap-down triggers an ugly rout
Seven months after Ampio Pharmaceuticals $AMPE gave its long-suffering investors something to cheer about with their report that a third try at a pivotal study …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
